m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00529)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
IL-6
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 14 (METTL14) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14 | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Treatment: siMETTL14 MDA-MB-231 cells
Control: MDA-MB-231 cells
|
GSE81164 | |
Regulation |
|
logFC: 1.55E+00 p-value: 4.20E-30 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Mettl14 gene knockout significantly reduced the inflammatory response of macrophages and the development of atherosclerotic plaques, Mettl14 plays a vital role in macrophage inflammation in atherosclerosis via the NF-Kappa-B/Interleukin-6 (IL-6) signaling pathway. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Atherosclerosis | ICD-11: BD40.Z | ||
Pathway Response | IL-17 signaling pathway | hsa04657 | ||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
In-vivo Model | Mettl14 heterozygous mice (Mettl14-/+) were established from C57/BL6 mice by Cyagen Biosciences, Inc. (Suzhou, Jiangsu, China), using CRISPR/Cas9-based targeting and homology-directed repair. C57/BL6 and APOE-/- mice were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China). Mettl14-/+APOE-/- mice were generated by breeding Mettl14-/+ mice with APOE-/- mice. Eight- to 10-week-old male APOE-/- (WT) mice and Mettl14-/+APOE-/- (KO) mice were fed a high-cholesterol diet (D12108C, Opensource diets) for 12 weeks. Then, the mice were euthanized for further analysis. | |||
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | ARPE-19 cell line | Homo sapiens |
Treatment: shMETTL3 ARPE-19 cells
Control: shControl ARPE-19 cells
|
GSE202017 | |
Regulation |
|
logFC: -1.10E+00 p-value: 7.68E-04 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 knockdown suppressed Interleukin-6 (IL-6), matrix metalloproteinase (MMP)-3, and MMP-9 levels in human RA-FLSs and rat AIA-FLSs. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Rheumatoid arthritis | ICD-11: FA20 | ||
Cell Process | Inflammatory response | |||
In-vitro Model | FLS (Rat fibroblast synovial cell line) | |||
In-vivo Model | To establish the adjuvant-induced arthritis (AIA) model, the rats were given complete Freund's adjuvant (CFA; Chondrex, Inc.) on the left paw of 0.1 ml per 100 g of body weight. Additionally, the rats were injected with normal saline to create the negative control (NC) group. | |||
YTH domain-containing protein 2 (YTHDC2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | This modification recruits the m6A reader YTHDC2 and found that YTHDC2 is necessary for the escape of the IL-6 transcript. m6A modification is essential to confer SOX resistance to the Interleukin-6 (IL-6) mRNA. These results shed light on how the host cell has evolved to use RNA modifications to circumvent viral manipulation of RNA fate during KSHV infection Kaposi's sarcoma. | |||
Responsed Disease | Kaposi's sarcoma | ICD-11: 2B57 | ||
In-vitro Model | iSLK.219 | Clear cell renal cell carcinoma | Homo sapiens | CVCL_B6YV |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HEK293 | Normal | Homo sapiens | CVCL_0045 | |
Kaposi's sarcoma [ICD-11: 2B57]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | This modification recruits the m6A reader YTHDC2 and found that YTHDC2 is necessary for the escape of the IL-6 transcript. m6A modification is essential to confer SOX resistance to the Interleukin-6 (IL-6) mRNA. These results shed light on how the host cell has evolved to use RNA modifications to circumvent viral manipulation of RNA fate during KSHV infection Kaposi's sarcoma. | |||
Responsed Disease | Kaposi's sarcoma [ICD-11: 2B57] | |||
Target Regulator | YTH domain-containing protein 2 (YTHDC2) | READER | ||
In-vitro Model | iSLK.219 | Clear cell renal cell carcinoma | Homo sapiens | CVCL_B6YV |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HEK293 | Normal | Homo sapiens | CVCL_0045 | |
Atherosclerosis [ICD-11: BD40]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Mettl14 gene knockout significantly reduced the inflammatory response of macrophages and the development of atherosclerotic plaques, Mettl14 plays a vital role in macrophage inflammation in atherosclerosis via the NF-Kappa-B/Interleukin-6 (IL-6) signaling pathway. | |||
Responsed Disease | Atherosclerosis [ICD-11: BD40.Z] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | IL-17 signaling pathway | hsa04657 | ||
In-vitro Model | THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 |
In-vivo Model | Mettl14 heterozygous mice (Mettl14-/+) were established from C57/BL6 mice by Cyagen Biosciences, Inc. (Suzhou, Jiangsu, China), using CRISPR/Cas9-based targeting and homology-directed repair. C57/BL6 and APOE-/- mice were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China). Mettl14-/+APOE-/- mice were generated by breeding Mettl14-/+ mice with APOE-/- mice. Eight- to 10-week-old male APOE-/- (WT) mice and Mettl14-/+APOE-/- (KO) mice were fed a high-cholesterol diet (D12108C, Opensource diets) for 12 weeks. Then, the mice were euthanized for further analysis. | |||
Rheumatoid arthritis [ICD-11: FA20]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 knockdown suppressed Interleukin-6 (IL-6), matrix metalloproteinase (MMP)-3, and MMP-9 levels in human RA-FLSs and rat AIA-FLSs. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Inflammatory response | |||
In-vitro Model | FLS (Rat fibroblast synovial cell line) | |||
In-vivo Model | To establish the adjuvant-induced arthritis (AIA) model, the rats were given complete Freund's adjuvant (CFA; Chondrex, Inc.) on the left paw of 0.1 ml per 100 g of body weight. Additionally, the rats were injected with normal saline to create the negative control (NC) group. | |||
References